Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.51 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | SCN1A | P35498 | 1/20 | 0.45 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.45 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.43 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28036717 | 0.92 | KDM4E (0.59) | KDM4EPDCD1CD274SLC1A5SMN1; SMN2 | |
| Aniline SCHEMBL15936355 | 0.88 | LMNA (0.54) | CYP3A4HSD17B10TDP1SMN1; SMN2MAPT | |
| SCHEMBL13310823 | 0.84 | CA12 (0.47) | KDM4EPDCD1CD274TDP1SLC1A5 | |
| Aniline SCHEMBL4252018 | 0.84 | NPC1 (0.50) | CYP3A4TDP1SMN1; SMN2NPC1RAB9A | |
| Aniline SCHEMBL4256412 | 0.84 | CES2 (0.50) | TAAR1SMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL1000847 | 0.82 | LMNA (0.57) | CYP3A4TDP1MAPTNPC1RAB9A | |
| Aniline SCHEMBL4258488 | 0.81 | CES2 (0.56) | KDM4ECYP3A4TDP1SMN1; SMN2MAPT | |
| SCHEMBL15120801 | 0.80 | BCL2L1 (0.54) | KDM4EPDCD1CD274HSD17B10EGFR | |
| SCHEMBL72340 | 0.80 | LMNA (0.64) | KDM4ECYP3A4HSD17B10TDP1SMN1; SMN2 | |
| SCHEMBL9138584 | 0.78 | LMNA (0.61) | KDM4ECYP3A4HSD17B10TDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745022-B1 | HISTONE DEACETYLASE INHIBITOR PRODRUGS | ATON PHARMA INC (US) | 2014-08-13 | — | — | EP | claimed |
| US-8227636-B2 | Histone deacetylase inhibitor prodrugs | MERCK HDAC RESEARCH, LLC (US) | 2012-07-24 | — | — | US | claimed |
| EP-1745022-B1 | HISTONE DEACETYLASE INHIBITOR PRODRUGS | ATON PHARMA INC (US) | 2014-08-13 | — | — | EP | disclosed |
| US-8227636-B2 | Histone deacetylase inhibitor prodrugs | MERCK HDAC RESEARCH, LLC (US) | 2012-07-24 | — | — | US | disclosed |
| US-20090023786-A1 | Histone Deacetylase Inhibitor Prodrugs | ALTON PHARMA, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| EP-1745022-A1 | HISTONE DEACETYLASE INHIBITOR PRODRUGS | Aton Pharma, Inc. (US) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005097747-A1 | HISTONE DEACETYLASE INHIBITOR PRODRUGS | ATON PHARMA, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023786-A1 | Histone Deacetylase Inhibitor Prodrugs | HDAC1, HDAC5, HDAC7 | KDM4E 581/4885PDCD1 1129/4885CD274 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.